Key result
Agalsidase alfa stabilizes wall thickness and LVOT gradients in obstructive Fabry cardiomyopathy.
Why the study?
Fabry cardiomyopathy can present with a hypertrophic phenotype and left ventricular outflow tract obstruction mimicking obstructive hypertrophic cardiomyopathy, leading to misdiagnosis and inappropriate treatment.
Does enzyme replacement therapy ameliorate left ventricular outflow tract obstruction in patients with Fabry cardiomyopathy misdiagnosed as obstructive hypertrophic cardiomyopathy?
Case Report (n=3)
Does enzyme replacement therapy ameliorate left ventricular outflow tract obstruction in patients with Fabry cardiomyopathy misdiagnosed as obstructive hypertrophic cardiomyopathy?
Fabry cardiomyopathy can mimic obstructive hypertrophic cardiomyopathy, emphasizing the need for routine genetic testing in unexplained LVH to avoid inappropriate phenotype-directed therapies and facilitate timely enzyme replacement therapy.
Answers are grounded in this paper and cite their sources.
May support ERT consideration for LVOTO in Fabry-mimic oHCM; hypothesis-generating and leaves open confirmation in prospective trials.
Background: Fabry disease is a cardiomyopathy with multisystemic manifestations that is easily to be misdiagnosed as another type of cardiomyopathy. Fabry cardiomyopathy may present with left ventricular outflow tract obstruction (LVOTO), mimicking obstructive hypertrophic cardiomyopathy (oHCM). We present three cases of genetically confirmed Fabry disease that were initially misdiagnosed as oHCM, highlighting the importance of early recognition and tailored management. Methods: We performed Fabry disease screening on patients diagnosed with oHCM and ultimately identified three individuals who have received oHCM-specific treatments including mavacamten and alcohol septal ablation. Results: Three patients (2 females, 1 male; aged 48-66 years) who were initially diagnosed with and managed for oHCM based on septal hypertrophy and elevated left ventricular outflow tract gradients (LVOTG), was found to have GLA gene mutations. Enzyme replacement therapy with agalsidase alfa in two patients was associated with stabilization or improvement in wall thickness and LVOTO. Conclusion: Fabry cardiomyopathy can present with a hypertrophic phenotype and significant LVOTO, and is often misdiagnosed as oHCM. This further underscores the importance of genetic testing in the etiological diagnosis of hypertrophic cardiomyopathies. Enzyme replacement therapy may ameliorate obstruction, while mavacamten and septal reduction therapies require caution without definitive genotype-phenotype correlation.
No takes yet. Share an insight, caveat, or question.
Hosyanto et al. (2026) conducted a case report in Fabry cardiomyopathy presenting as obstructive hypertrophic cardiomyopathy (oHCM) (n=3). Enzyme replacement therapy (agalsidase alfa) was evaluated on Stabilization or improvement in left ventricular wall thickness and left ventricular outflow tract obstruction (LVOTO). Enzyme replacement therapy with agalsidase alfa stabilized or improved wall thickness and left ventricular outflow tract gradients in patients with Fabry cardiomyopathy mimicking obstructive HCM.
Synapse has enriched 10 related papers. Consider them for comparative context: